Bendamustine ( DrugBank: Bendamustine )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
28	全身性アミロイドーシス	2
61	自己免疫性溶血性貧血	4

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05451771 (ClinicalTrials.gov)	October 26, 2022	6/7/2022	Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Sy ...	AL Amyloidosis	Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: D ...	Rajshekhar Chakraborty, MD	Genentech, Inc.	Recruiting	18 Years	N/A	All	53	Phase 1/Phase 2	United States
2	NCT01222260 (ClinicalTrials.gov)	January 2013	14/10/2010	Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis	Phase II Study of the Combination of Bendamustineand Dexamethasone in Patients With Relapsed AL Amyl ...	AL Amyloidosis	Drug: Bendamustine;Drug: Dexamethasone	Columbia University	Cephalon	Completed	18 Years	N/A	All	40	Phase 2	United States

First Previous1Next Last

61. 自己免疫性溶血性貧血

臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-004835-30-FI (EUCTR)	10/07/2013	17/06/2013	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [ ...	Trade Name: Levact INN or Proposed INN: BENDAMUSTINEHYDROCHLORIDE Trade Name: MabThera INN or Proposed ...	Department of Medicine, Haugesund Hospital	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Finland;Denmark;Norway
2	EUCTR2011-004835-30-DK (EUCTR)	17/01/2013	30/11/2012	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [ ...	Trade Name: Levact INN or Proposed INN: BENDAMUSTINEHYDROCHLORIDE Trade Name: MabThera INN or Proposed ...	Department of Medicine, Haugesund Hospital	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Finland;Denmark;Norway
3	NCT02689986 (ClinicalTrials.gov)	January 2013	16/2/2016	Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease	The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized Internati ...	Cold Agglutinin Disease;Autoimmune Hemolytic Anemia	Drug: Bendamustine, Rituximab	Helse Fonna	NULL	Completed	18 Years	N/A	All	43	Phase 2	Denmark;Finland;Norway
4	EUCTR2011-004835-30-NO (EUCTR)	23/10/2012	29/08/2012	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Therapy for chronic cold agglutinin disease: A prospective,non-randomized international multicenter ...	Primary chronic cold agglutinin disease requiringtreatment;Therapeutic area: Diseases [C] - Cancer [ ...	Trade Name: Levact INN or Proposed INN: BENDAMUSTINEHYDROCHLORIDE Trade Name: MabThera INN or Proposed ...	Department of Medicine, Haugesund Hospital	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Finland;Denmark;Norway

First Previous1Next Last

先頭へ